Soft-tissue Filler–associated Blindness: A Systematic Review of Case Reports and Case Series

Vandana Chatrath, MSc*†
Pooja S. Banerjee, MPharm‡
Greg J. Goodman, MD, FACDS§
Egram Rahman, MBBS, MS, PhD¶

Background: With the increase in the use of soft-tissue fillers worldwide, there has been a rise in the serious adverse events such as vascular compromise and blindness. This article aims to review the role of fillers in causing blindness and the association between hyaluronic acid (HA) filler and blindness.

Methods: The Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used to report this review.

Results: A total of 190 cases of blindness due to soft-tissue fillers were identified, of which 90 (47%) cases were attributed to autologous fat alone, and 53 (28%) cases were caused by HA. The rest of the cases were attributed to collagen, calcium hydroxylapatite, and other fillers.

Conclusions: Autologous fat was the most common filler associated with blindness despite HA fillers being the most commonly used across the globe. However, the blindness caused by other soft-tissue fillers like collagen and calcium hydroxylapatite was represented. It was also evident through the review that the treatment of HA-related blindness was likely to have better outcomes compared with other fillers due to hyaluronidase use. (Plast Reconstr Surg Glob Open 2019;7:e2173; doi: 10.1097/GOX.0000000000002173; Published online 2 April 2019.)

INTRODUCTION

“Beauty” is a universal phenomenon that transcends geographical boundaries and cultures. Its occurrence or attainment influences self-confidence, improves psychological standing, and elevates personal and professional capabilities.1 Minimally invasive cosmetic procedures have increased relative to other aspects of cosmetic surgery due to its advantages of achieving a subtle natural appearance, restoring natural contour, reducing morbidity, requiring less downtime posttreatment, and the easy availability of these procedures.2

A plethora of soft-tissue fillers for facial aesthetic correction ranging from autologous fat, polymethylmethacrylate, calcium hydroxylapatite, poly-L-Lactic acid, polycaprolactone, and hyaluronic acid (HA) are available. Of these, HA is the most widely used filler (over 2 million) with the longevity of approximately 6–24 months depending on the molecular size, a method of cross-linking, and the region of injection.3 Fillers have been traditionally associated with mild and transient adverse events such as bruising, swelling, infection, and surface irregularities. However, with the increased use of fillers worldwide, more serious and permanent adverse events such as vascular compromise and blindness are on the rise.4 Vision loss is a rare adverse event but catastrophic to both patient and the physician.5

With the increase in the availability of the soft-tissue fillers, number of aesthetic practitioners, and demand for aesthetic procedures globally, the usage of fillers is expected to rise. It is imperative that aesthetic physicians have a firm knowledge of the vascular anatomy and understand potential complications, critical prevention, and management strategies.6,7

The present systematic review has been conducted to elucidate the occurrence of blindness with various soft-tissue fillers, the association between HA filler and blindness, and to review factors influencing the development of blindness. We aim to fill in the gap between the existing practice and knowledge about the adverse effect of blindness in relation to the use of soft-tissue fillers, so that clinicians can make evidence-based decisions.

Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

From the *Postgraduate Medical Institute, Faculty of Medical Sciences, Anglia Ruskin University, Chelmsford, Essex, CM1 1SQ United Kingdom; †Delhi Dermatology Group, New Delhi, India; ‡IFCP Group of Publications, New Delhi, India; §Monash University, Clayton, Victoria, Australia; and ¶Institute of Medical and Biomedical Education, St. George’s University of London, Cranmer Terrace, Tooting Broadway, SW17 0RE London, United Kingdom. Received for publication October 22, 2018; accepted January 8, 2019.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/GOX.0000000000002173
METHODS

A systematic review of the published literature was conducted to assess the association of blindness with the soft-tissue filler injections. The Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used to report this review.8

Criteria for Considering Studies for the Review

Inclusion Criteria

The relevant articles that met the following criteria were selected.

1. Original articles and expert’s opinions published between January 2000 and September 2018 that investigated or discussed the role of soft-tissue fillers (HA fillers, autologous fat, calcium hydroxylapatite or collagen, and others) in causing blindness.
2. Articles published in English Language only.

Exclusion Criteria

We excluded the following articles:

1. in which patients underwent surgical correction,
2. where injections of nonfiller materials (corticosteroids) were given,
3. where vascular complications other than blindness were discussed, and
4. posters/abstracts and studies on animal models.

Literature Search

The goal was to analyze all the published literature comprising original research, clinical trials, case reports, retrospective and prospective case studies, systematic reviews and meta-analysis. A search of the computerized bibliographic database: Medline, Cochrane, PubMed, Google, and Google Scholar were performed. The MeSH terms used in the search were: tissues; blindness; injections; face; cosmetics; HA, including additional search terms like blindness; soft; filler; fat; hyaluronic; and autologous fat. The favorite key phrases used for search included cosmetic injections; facial aesthetics; soft-tissue fillers; hyaluronic acid; soft-tissue fillers; injectables; blindness; vision loss; acquired blindness; autologous fat; collagen; and calcium hydroxylapatite. In a backward chronological search, the bibliographies of all relevant articles were checked for citations that could not be identified in our primary search. The primary search strategy is outlined in Table 1.

Screening

Titles and abstracts from the electronic search were screened, and full-text manuscripts meeting the selection criteria were obtained. Crucial information from all the articles such as study design, number of cases, adverse effects, the funder used, mechanism, treatment, or any other pertinent data was extracted. Two investigators (V.C. and P.S.B.) independently extracted data from eligible studies, and any differences were resolved through discussion and consensus between the authors. When a consensus was not reached, arbitration was done by the third author (E.R.).

Table 1. Main Search Strategy for PubMed

| Search Items |
|-------------|
| Primary     |
| “blindness”[MeSH Terms] OR “blindness”[All Fields] |
| “tissues”[MeSH Terms] OR “tissues”[All Fields] OR “tissue”[All Fields] |
| “cosmetics”[Pharmacological Action] OR “cosmetics”[MeSH Terms] OR “cosmetics”[All Fields] OR “cosmetic”[MeSH Terms] OR “cosmetics”[All Fields] OR “cosmetic”[All Fields] |
| “face”[MeSH Terms] OR “face”[All Fields] OR “facial”[All Fields] |
| injections”[MeSH Terms] OR “injections”[All Fields] |
| “durapatite”[MeSH Terms] OR “durapatite”[All Fields] OR “hydroxyapatite”[All Fields] |

Extended

{“blindness”[MeSH Terms] OR “blindness”[All Fields]} AND SOFT[All Fields] AND (“tissues”[MeSH Terms] OR “tissues”[All Fields] OR “tissue”[All Fields]) AND FILLERS[All Fields] AND AUTOLOGOUS[All Fields] AND FAT[All Fields] 
{“blindness”[MeSH Terms] OR “blindness”[All Fields]} AND (“cosmetics”[Pharmacological Action] OR “cosmetics”[MeSH Terms] OR “cosmetics”[All Fields] OR “cosmetic”[All Fields]) AND (“face”[MeSH Terms] OR “face”[All Fields]) OR (“tissues”[MeSH Terms] OR “tissues”[All Fields]) AND FILLERS[All Fields] AND (“injections”[MeSH Terms] OR “injections”[All Fields]) |
{“blindness”[MeSH Terms] OR “blindness”[All Fields]} AND (“durapatite”[MeSH Terms] OR “durapatite”[All Fields] OR “hydroxyapatite”[All Fields]) AND (“injections”[MeSH Terms] OR “injections”[All Fields] OR “injection”[All Fields]) |

Boolean: 1 AND 2
Date limit: (“2000/01/01”[PDAT]: “2018/09/15”[PDAT])

The selected articles were then qualitatively and quantitatively analyzed by the investigators. The process of screening, selection, and the inclusion of eligible articles and reasons for exclusion were displayed in Figure 1.

Data Items, Extraction, and Synthesis

The data were retrieved by reading the entire article. Papers were reported in a table with the following fields: record number, the name of the author(s), publication year, article title, and journal. Relevant data from eligible full texts were extracted by 2 authors (V.C. and P.S.B.) using prestructured data abstraction sheets. Two data abstraction sheets were predesigned to extract available data on the author, year of case reporting with a number of cases, geographic region, type of soft-tissue filler used, the anatomical area of injection, and any ocular complication and recovery. The disagreements were resolved as detailed above.

Assessment of Methodological Quality

A validated tool for the determination of the methodological quality of the case reports and case series proposed by Murad et al9 based on the previous criteria from Piersen, Bradford Hills, and Newcastle-Ottawa scale modifications was used. Each case study or series was evaluated under 4 domains (selection, ascertainment, causality, and reporting) that are summarized in Table 1. This resulted in 8 leading exploratory questions with a binary response (yes/no), whether the item was suggestive of bias or not. No disagreements were found between the reviewers.

Data Synthesis and Analysis

Due to the small number and evident heterogeneity among the included studies reporting on a wide variety of risk factors associated with ocular complication, the
findings herein were presented using tables and narrative summaries.

**RESULTS**

A total of 190 cases of filler-induced blindness were identified in the present study. The maximum cases of filler-induced blindness or other ocular disturbances were attributed to autologous fat injections (90 cases; 47%). The second most prominent cause of filler-induced blindness was due to HA (53 cases; 28%), whereas rest of the cases were attributed to collagen, calcium hydroxylapatite, and other fillers. However, it is interesting to note that 11 HA-related blindness cases had significant improvement in visual acuity and 6 cases of complete vision restoration when treated with hyaluronidase. The visual outcome was not good in any other filler-induced blindness. It is also notable that 8 cases of calcium hydroxylapatite (CaHA)–induced blindness were reported between 2014 and 2018. Figures 2 and 3 depict the number of blindness cases caused by various soft-tissue fillers and the percentage of reported blindness according to the injection site.
Blindness Associated with Soft-tissue Fillers

Vascular occlusion is a rare but severe and dreaded complication of soft-tissue fillers. It occurs because of inadvertent injection of the filler material in a blood vessel. This intravascular injection of fillers may lead to complications such as tissue ischemia and loss, blindness, pulmonary embolization, and even stroke. In a recent study published by Povolotskiy et al investigating the adverse events arising with various aesthetic fillers, vascular complications were cited to be among some of the commonly occurring complications. This study comprised 5,024 cases, out of which vascular complications were observed in 590 cases. Even though blindness caused by soft-tissue fillers is an infrequent event, it is a matter of great concern owing to its distressing consequences. The causative agents that may lead to blindness include autologous fat, HA, collagen, poly-L-Lactic acid, calcium hydroxylapatite, and even corticosteroid suspensions. Vision loss manifests as an immediate complication of facial filler injection with other associated signs and symptoms depending on the location of vascular occlusion.

Rzany and DeLorenzi reported in a small retrospective study that vascular occlusions, such as of ophthalmic and/or retinal artery resulting in blindness, are apparently more common and more severe in non-HA fillers. A review by Beleznay et al demonstrated that the incidence of vascular occlusion following an injection of a filler is estimated to be approximately 3–1,000 in case of calcium hydroxylapatite, whereas 3–9 per 10,000 for HA preparations. It was also suggested that vascular complications and sequelae were more severe with non-HA fillers such as calcium hydroxyapatite and polymethylmethacrylate.

Beleznay et al showed that almost 47.9% of cases of blindness were caused by autologous fat, whereas HA fillers were responsible for 23.5% of the cases which are consistent with the present finding. Autologous fat, the most viscous soft-tissue filler had the highest risk of diffuse occlusion in the ophthalmic artery and was also associated with poor prognosis.

In a retrospective study conducted between January 1, 2008 and August 31, 2014, Kim et al also observed that the prevalence of diffuse occlusion of ophthalmic artery and its branches is less in HA-injected patients compared with autologous fat-injected group. This could be attributed to the difference in the particle sizes of the 2 fillers. Autologous fat has a variable particle size, whereas HA particles are approximately 400 μm in size. Hyaluronic acid fillers are more likely to block the central retinal artery (approximately 160 μm in size) or its smaller branches and fat more likely the ophthalmic artery (2 mm in diameter) due to the particle size and the amount of filler injected per injection site. While studying fundus artery occlusion also found that the prognosis was found to be much worse in autologous fat than in HA.

Previous studies have also reported that injections with autologous fat are associated with a higher diffuse occlusion rate, resulting in a much worse visual prognosis and more frequent cerebral infarctions compared with HA.

The Mechanism for HA-induced Blindness versus Blindness Induced by Other Fillers

Currently, it is thought that an accidental injection of fillers into the blood vessel can lead to the formation of tissue filler emboli. Various authors have suggested that the mechanism of this is most likely through initially retrograde flow against the prevailing blood pressure to a point at or past the retinal branches. Consequent release of the syringe pressure allows the usual blood pressure to reestablish the antegrade blood flow carrying forward these emboli allowing them to enter the ophthalmic artery circulation. This embolus is responsible for retinal ischemic necrosis. The ophthalmic artery branches with cutaneous innervation (supplying the glabella, nose periorbital zone, and forehead) probably carry the greatest risk, but anastom-

**DISCUSSION**

**Fig. 3.** Percentage of reported filler-associated blindness according to the injection site.
moses between facial artery and branches of the ophthalmic artery have been shown in cadaveric studies. 49

A cadaveric study published in June 2018 has suggested that retrograde HA filler emboli to the ophthalmic artery may be a result of the cannulation of the supratrochlear artery, primarily due to its superficial location surrounded by rich vasculature and a variable anatomy.54  Sufan et al 55 published an article in 2017 which showed that in the glabella region, the deep injection on the periosteum will be at risk of entering the supratrochlear artery and supraorbital artery, whereas, in nasal dorsum and nasolabial folds, the subsuperficial musculoaponeurotic system layer injection has the possibility to enter the dorsal nasal artery, angular artery, and facial artery.

It has also been suggested that the volume of the filler injected, and the pressure of injection can impact the outcome of blindness by influencing the retrograde flow of the filler into the ophthalmic circulation. The amount of soft-tissue filler injected varies according to the type of filler used, for example, autologous fat is typically injected in larger volumes compared with HA fillers. 56

Even though both fat and HA fillers may cause vision loss, the occlusion of the ophthalmic circulation vessels would vary due to the particle size and the amount of filler injected per injection site. This could explain why the case series by Park et al. showed that autologous fat was associated with a higher diffuse occlusion with worse visual prognosis and a higher incidence of concomitant cerebral infarction.13,23

The speed and pressure of injection have also been proposed to influence the flow of the filler after its inadvertent injection into the vessel. This has a direct impact on the speed and pressure of injection as the viscosity of the filler influences the extrusion force (injection pressure) used by the injector that will then determine the speed and pressure of injection finally affecting the flow of the filler within the vessel. A highly viscous filler (like

### Table 2. Qualitative Assessment of the Included Studies

| References                        | Selection | Ascertainment | Causality | Reporting |
|-----------------------------------|-----------|---------------|-----------|-----------|
| Danesh-Meyerr et al. 10           | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Silva and Curti11                 | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Mori et al.32                     | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Park et al.33                     | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Sung et al.34                     | Yes       | Yes           | Yes       | No        | Yes       |
| Lee et al.35                      | Yes       | Yes           | Yes       | No        | Yes       |
| Park and Kim46                    | Yes       | Yes           | Yes       | No        | Yes       |
| Lee et al.37                      | Yes       | Yes           | Yes       | No        | Yes       |
| Lazerri et al.38                  | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Park et al.40                     | Yes       | Yes           | Yes       | No        | Yes       |
| Ozturk et al.40                   | Yes       | Yes           | Yes       | No        | Yes       |
| Kim et al.21                      | Yes       | Yes           | Yes       | No        | Yes       |
| Chen et al.22                     | Yes       | Yes           | Yes       | No        | Yes       |
| Carle et al.23                    | Yes       | Yes           | Yes       | No        | Yes       |
| Park et al.24                     | Yes       | Yes           | Yes       | No        | Yes       |
| Hong et al.25                     | Yes       | Yes           | Yes       | No        | Yes       |
| Chang et al.26                    | Yes       | Yes           | Yes       | No        | Yes       |
| Lee et al.27                      | Yes       | Yes           | Yes       | No        | No        | No        |
| Kim et al.28                      | Yes       | Yes           | Yes       | No        | Yes       |
| Hsieh et al.29                    | Yes       | Yes           | Yes       | No        | Yes       |
| Chou et al.20                     | Yes       | Yes           | Yes       | No        | Yes       |
| Zhu et al.40                      | Yes       | Yes           | Yes       | No        | Yes       |
| Chen et al.32                     | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Hu et al.33                       | Yes       | Yes           | Yes       | No        | Yes       |
| Cohen et al.34                    | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Goodman and Clague35             | Yes       | Yes           | Yes       | No        | Yes       |
| Dagi et al.36                     | Yes       | Yes           | Yes       | No        | No        | Yes       |
| Lee et al.37                      | Yes       | Yes           | Yes       | No        | Yes       |
| Myung et al.39                    | Yes       | Yes           | Yes       | No        | Yes       |
| Sanytr et al.38                   | Yes       | Yes           | Yes       | No        | Yes       |
| Marumo et al.41                   | Yes       | Yes           | Yes       | No        | Yes       |
| Sharudin et al.42                 | Yes       | Yes           | Yes       | No        | No        | No        |
| Thnasarnaksorn et al.43          | Yes       | Yes           | Yes       | No        | Yes       |
| Chesnut44                         | Yes       | Yes           | Yes       | No        | Yes       |
| Lim et al.45                      | Yes       | Yes           | Yes       | No        | Yes       |

**Selection:** 1. Does the patient(s) represent(s) the whole experience of the investigator (center) or is the selection method unclear to the extent that other patients with similar presentation may not have been reported? 2. Was the exposure adequately ascertained? 3. Was the outcome adequately ascertained? 4. Were other alternative causes that may explain the observation ruled out? 5. Was there a challenge/rechallenge phenomenon? 6. Was there a dose–response effect? 7. Was follow-up long enough for outcomes to occur? 8. Is the case(s) described with sufficient details to allow other investigators to replicate the research or to allow practitioners make inferences related to their own practice?

**Ascertainment:** 2. Was the exposure adequately ascertained? 3. Was the outcome adequately ascertained? 4. Were other alternative causes that may explain the observation ruled out? 5. Was there a challenge/rechallenge phenomenon? 6. Was there a dose–response effect? 7. Was follow-up long enough for outcomes to occur? 8. Is the case(s) described with sufficient details to allow other investigators to replicate the research or to allow practitioners make inferences related to their own practice?
(fat) will require a higher extrusion force compared with a filler that is less viscous.

Another factor influencing the extrusion force is the size of the syringe and gauge of the needle/cannula which is determined by choice of the soft-tissue filler used. Typically, autologous fat is injected using large gauge needles and an increased force used to inject it would be easier to produce increasing the likelihood of a large bolus if intravascular penetration occurs.

Interestingly, the propensity of soft-tissue fillers in activating clotting mechanism also influences their effect. The noninflammatory fillers may purely cause a mechanical obstruction when placed within the blood vessel. However, others can activate an intravascular inflammatory

### Table 3. Characteristics of Studies Included

| References                  | Region                  | Type of Study (No. Cases) | Type of Soft-tissue Filler | Location of Injection                                      |
|-----------------------------|-------------------------|---------------------------|----------------------------|-----------------------------------------------------------|
| Danesh-Meyerr et al.10      | United States           | Case report (1)           | Autologous fat             | The left side of the bridge of the nose                  |
| Silva and Curi11            | Brazil                  | Case report (1)           | PMMA                       | Glabellar region                                         |
| Mori et al.12               | Japan                   | Case report (1)           | Autologous fat             | Glabellar region and nose                                |
| Park et al.13               | Korea                   | Case report (1)           | Autologous fat             | Right nasolbal fold                                     |
| Sung et al.14               | Korea                   | Case report (1)           | Calcium hydroxylapatite    | Nose                                                     |
| Lee et al.15                | Korea                   | Case report (1)           | Autologous fat             | Forehead                                                 |
| Park and Kim16              | Korea                   | Case report (1)           | Autologous fat             | Periocular area                                          |
| Lazerri et al.18            | Korea                   | Case review (32)          | Autologous fat injection (15); nonfat filler injection (coriostereoids, paraffin, silicone oil, bovine collagen, PMMA, HA, calcium hydroxylapatite (n = 17) |                                                                       |
| Park et al.19               | Retrospective, noncomparative case series (12) | Case report (1) | Autologous fat (n = 7), HA (n = 4), and collagen (n = 1) | Glabellar region (n = 7), nasolbal fold (n = 4), and both (n = 1) |
| Ozturk et al.20             | United States, Brazil, Japan, and Korea | Review of case reports (12) | Collagen (n = 3), injectable soft-tissue matrix (n = 1), PMMA (n = 2), HA (2), CaHa (n = 1), PLLA (n = 1), and NR (n = 2) | Glabellar, cheek (n = 2), forehead (n = 1), glabella (n = 4), nose septum (n = 1), nose tip (n = 1), and periorbital region (n = 1) |
| Kim et al.21                | South Korea             | Case report (1)           | HA                         | Nose dorsal                                              |
| Chen et al.22               | China                   | Case review (13)          | Autologous fat (n = 7), HA (n = 5), and bone collagen (n = 1) | Nasal area (n = 5), periorbital area (n = 2), nose area and nasal area (n = 4) |
| Carle et al.23              | United States           | Case reports (3)          | HA (n = 1), autologous fat (n = 1), and PMMA microspheres (n = 1) | Forehead                                                 |
| Park et al.24               | Korea                   | National survey, case reports (44) | Autologous fat injection (n = 22), HA (n = 15), collagen n = 4, and others (n = 5) | Glabella (n = 26), nasolbal fold (n = 11), and nasal dorsal, rhinoplasty (n = 10) |
| Hong et al.25               | Korea                   | Case report (1)           | Autologous fat             | Glabellar area (n = 3), nasolbal area (n = 5), forehead area (n = 4), periorbital area (n = 2), nose area and nasal area (n = 2), multiple places (n = 2), and other areas (n = 5) |
| Chang et al.26              | Taiwan                  | Case report (1)           | Calcium hydroxylapatite    | Nose                                                     |
| Lee et al.27                | Korea                   | Case report (1)           | HA                         | Glabellar area (n = 1) and nose (n = 1)                  |
| Kim et al.28                | Korea                   | Case report (1)           | HA                         | Nose                                                     |
| Hsich et al.29              | Taiwan                  | Case reports (2)          | Calcium hydroxylapatite    | Glabellar (n = 1) and nose (n = 1)                       |
| Chou et al.30               | Taiwan                  | Case report (1)           | Calcium hydroxylapatite    | Nose                                                     |
| Qi et al.31                 | China                   | Retrospective noncomparative case series (27) | Autologous fat             | Glabellar area (n = 3), nasolbal area (n = 5), forehead area (n = 4), periorbital area (n = 2), nose area and nasal area (n = 2), multiple places (n = 2), and other areas (n = 5) |
| Chen et al.32               | China                   | Case report (1)           | HA                         | Nasal dorsal                                             |
| Hu et al.33                 | China                   | Case report (1)           | HA                         | Forehead                                                 |
| Cohen et al.34              | Israel                  | Case report (1)           | Calcium hydroxylapatite    | Nose bridge                                              |
| Goodman and Clague35        | Australia               | Case report (1)           | HA                         | Temple and brow                                          |
| Dagi et al.36               | United States           | Case report (1)           | Calcium hydroxylapatite    | Both temples, both cheeks, forehead, and the chin        |
| Lee et al.37                | Korea                   | Case report (1)           | HA                         | Left supraorbal and right forehead area                  |
| Szanty et al.38             | Poland                  | Case report (1)           | Autologous fat             | Glabellar (n = 5), nasolbal fold (n = 3), nasal dorsal (n = 3), and glabella and nasal dorsal (n = 2) |
| Myung et al.39              | Korea                   | Retrospective case review (9) | HA                         | Nose (n = 3) and forehead (n = 1)                        |
| Zhu et al.40                | China                   | Case series (4)           | HA                         | Glabellar (n = 1), nose dorsal (n = 1), and temple (n = 1) |
| Marumo et al.41             | Japan                   | Case report (1)           | Calcium hydroxylapatite    | Nose dorsal                                              |
| Sharudin et al.42           | China                   | Case report (1)           | HA                         | Nose (n = 4), forehead (n = 1), and temple (n = 1)       |
| Thesisarnakorn et al.43     | Thailand                | Case series (6)           | HA                         | Right-sided midface                                      |
| Chesnut44                   | United States           | Case reports (1)          | HA                         | Forehead                                                 |
| Liu et al.45                | China                   | Case reports (5)          | Autologous fat             |                                                          |
| References | Filler Used | Ocular Adverse Event | Management | Outcome |
|------------|------------|---------------------|------------|---------|
| Danesh-Meier et al. | Autologous fat | Ocular pain with vision loss, aphasic with right-sided hemiparesis, no light perception in left eye, and the left pupil amaurotic | Not reported (NR) | The left eye remained blind |
| Silva and Curi | Polymethylmethacrylate (PMMA) | Severe right ocular pain and visual loss after the injection | Drip infusion of urokinase and hyperbaric oxygen therapy; corticosteroids were also given at a later stage | She remains blind with total right ophthalmoplegia 10 mo after the procedure |
| Mori et al. | Autologous fat | Pain, visual loss in the right eye, widespread retina whitening | | No vision with complete obstruction of the right ophthalmic artery |
| Park et al. | Autologous fat | Sudden visual loss of her right eye | High-dose steroid therapy—methylprednisolone | No improvement in visual acuity |
| Sung et al. | Calcium hydroxylapatite | Blepharoptosis and orbital pain on the right side, associated with progressive visual disturbance of the right eye | The material was attempted to remove by aspiration, topical antibiotics, and steroids | After 3 mo, visual acuity, all intraocular inflammations, oculomotor nerve palsy resolved completely except for a dilated pupil |
| Lee et al. | Autologous fat | Ipsilateral ophthalmic artery occlusion with infarction of the optic nerve and retina | NR | Blindness in the left eye |
| Park and Kim | Autologous fat | Sudden, severe periorcular pain, complete vision loss in left eye | | Vision not improved at the 2-mo follow-up |
| Lee et al. | Autologous fat | Loss of vision in the left eye, ophthalmic artery occlusion, and left middle cerebral artery infarction | Ocular massage, intravenous mannitolization, and oxygen and carbon dioxide therapy | At 2 mo after the injection, the patient had no perception of light in the left eye, and the left fundus showed optic atrophy, multiple retinal hemorrhages and a fibrous change on its posterior pole |
| Lazerri et al. | Autologous fat injection (15); nonfat filler injection (corticosteroids, paraffin, silicone oil, bovine collagen, PMMA, HA, calcium hydroxylapatite) (n = 17) | Complaint of excruciating pain and a sudden blackout of the involved eye. Nonfat filler injection: blindness following the injection | Fat filler: no information about the treatment (n = 9), ocular massage, carbon dioxide rebreathing, hyperbaric oxygen therapy, oral and intravenous corticosteroids, antiplatelet drugs, fibrinolytic agents or mechanical thrombolysis (n = 6); nonfiller injection: systemic corticosteroids (n = 2), diuretic agents carbonic anhydrase inhibitors (n = 3), antiaggregant drugs (aspirin (n = 1 each), ocular massage (n = 5), surgical treatment—anterior chamber paracentesis (n = 1) | Fat filler injection: Neither the treated nor the untreated patients had any return of vision. Nonfiller injection: Only 3 patients recovered their site (1 patient recovered sight 5 min after injection of corticosteroids for alopecia areata; in another case, vision recovered completely and the visual field defect improved after prompt administration of acetazolamide; a healthy 25-35-old man had complete recovery of visual acuity, oculomotor nerve palsy, and skin necrosis after treatment with oral and topical corticosteroid tapers, although his dilated pupil did not improve), permanent visual loss without light perception persisted in all the remaining patients regardless of the type of the treatment |
| Park et al. | Autologous fat (n = 7), HA (n = 4), and collagen (n = 1) | Ophthalmic artery occlusion (n = 7), central retinal artery occlusion (n = 2), and branch retinal artery occlusion (n = 3) | Intravascular thrombolysis (n = 4), ACP (n = 3), Massage + Anterior chamber paracentesis (ACP) (n = 1), and Massage + Mannitol (n = 1) | All patients with ophthalmic artery occlusion had ocular pain and no improvement in best-corrected visual acuity |
| Ozturk et al. | Collagen (n = 3), injectable soft-tissue matrix (n = 1), PMMA (n = 2), HA (n = 2), CaHA (n = 1), poly-L-lactic acid (PLLA) (n = 1), and NR (n = 2) | 10 min: pain in the left eye, blurred vision (n = 1); immediate: severe pain and visual loss in the right eye (n = 1); 15 min: pain and visual loss in the right eye (n = 1); 1 min: partial loss of vision in inferior right visual field (n = 1); Immediate visual loss, necrosis of glabellar region (n = 1); Immediate: visual loss in the left eye (n = 4); Immediate: pain in the right eye, ptosis, ophthalmoplegia (n = 1) | Acetazolamide and methylprednisolone (n = 1); Antplatelet agent and calcium channel blocker (n = 1); Intravenous antibiotics, topical steroids, oral corticosteroids (n = 1); IV methylprednisolone, aspirin 100 mg orally (n = 1); Immediate acetazolamide (n = 1) | Vision loss with light perception (n = 1); Blindness and total ophthalmoplegia (n = 1); Blindness (n = 2); Complete recovery (n = 1); Partial recovery with 20/200 visual acuity (n = 1); Complete recovery with fixed dilated pupil (n = 1); Blindness, recovery from ophthalmoplegia (n = 2); NR (n = 3) |

(Continued)
### References Filler Used Ocular Adverse Event Management Outcome

| References | Filler Used | Ocular Adverse Event | Management | Outcome |
|------------|-------------|----------------------|------------|---------|
| Kim et al.21 | HA | Posis, ophthalmoplegia, and vision loss | High doses intravenous corticosteroids | At 6-mo follow-up, visual acuity and ophthalmoplegia in the right eye had not improved |
| Chen et al.22 | Autologous fat (n = 7), HA (n = 5), and bone collagen (n = 1) | Ophthalmic artery occlusion (n = 11), central retinal artery occlusion (n = 1), and anterior ischemic optic neuropathy (n = 1) | Treatment for fundus artery occlusion included nitro-glycerin, digital massage, eye drops to lower intraocular pressure, aspirin, ad prednisone. Laser treatment was panned retinal photocoagulation for the patients 1wk later if the patients were not convenient for close observation there were widespread vascular nonperfusion. Anterior chamber paracentesis, removal of aqueous to rapidly lower intraocular pressure, ocular massage, reactive hyperbaric oxygen therapy (n = 1) NR (n = 2) | Injected autologous fat was associated with worse final best corrected visual acuity (BCVA) than HA. The BCVA of 7 patients with autologous fat injection in the frontal area and temple area was no light perception. Most of the patients with ophthalmic artery occlusion (OAO) had ocular pain, headache, ptosis, ophthalmoplegia, and no improvement in final BCVA |
| Carle et al.23 | HA (n = 1), autologous fat (n = 1), and PMMA microspheres (n = 1) | Superior field visual loss in the left eye, blockage of inferior branches of the retinal circulation in the left eye (n = 1); immediate severe loss of vision (n = 1); immediate vision loss in the right eye, visual acuity was no light perception in right eye and 20/20 in left eye (n = 1) | NR | Right pupil minimally reactive to light and her visual acuity was a faint light perception in treatment case (n = 1); NR (n = 2) |
| Park et al.24 | Autologous fat injection (n = 22), HA (n = 15), collagen (n = 4), and others (n = 5) | Diffuse retinal and choroidal artery occlusions (ophthalmic artery occlusion, generalized posterior ciliary artery occlusion and central retinal artery occlusion) (n = 28); localized occlusions (localized posterior ciliary artery occlusion branch retinal artery occlusion, and posterior ischemic optic neuropathy) (n = 16) | NR | |
| Hong et al.25 | Autologous fat | Retinal artery occlusion with multiple cerebral infarctions | Ocular massage, anterior chamber paracentesis, volume expansion | After 5 mo, no light perception, the fundus of the right eye had a thick fibrous membrane on the posterior pole and optic atrophy |
| Chang et al.26 | Calcium hydroxylapatite | Acute onset left eye pain followed within a few hours by the progressive blurring of the vision of both eyes | Daily oral aspirin (100mg) and acetazolamide (250mg), a topical steroid 4 times per day, topical levofloxacin, and brimonidine 2 times per day, 95% oxygen therapy, and hydration with normal saline | No improvement on her visual acuity over 8 mo of follow-up |
| Lee et al.27 | HA | Visual loss in the left eye; central retinal artery occlusion | NR | After 3 mo of follow up, the visual acuity in the left eye was no light perception |
| Kim et al.28 | HA | Retrograde intravascular embolization into the small oculcar arteries | Filler was removed | Complete recovery |
| Hsieh et al.29 | Calcium hydroxylapatite | Sudden left eye blindness, no light perception in her left eye, with retinal cherry-red spots, moderate ptosis, limited eye movements (n = 1); sudden eye pain and visual impairment in the left eye, bilateral lower visual field defects (n = 1) | Anterior chamber paracentesis, timolol and acetazolamide (n = 1); hyperbaric oxygen therapy, systemic low dose steroids, antiaggregant, and topical and oral antiglaucomatous agents (n = 1) | No light perception in her left eye during follow-up (n = 1) altitudinal visual field defects in both eyes and generalized depression in the visual field of the left eye (n = 1) |
| Chou et al.30 | Calcium hydroxylapatite | Posis, left periordial pain, headache, after 30min progressively blurring vision in the eye | Alprostadil and dextran + 10 sessions of hyperbaric oxygen therapy | Visual acuity in her left eye improved to 6/60 after 1 mo |
| Qi et al.31 | Autologous fat | Sudden visual loss immediately after the injections. Ophthalmic artery occlusion (n = 13); central retinal artery occlusion (n = 6); branch retinal artery (n = 3) | Ocular massage, oxygen, and carbon dioxide therapy, hyperbaric oxygen therapy, steroid therapy, topical antibiotics, and anticoagulant | No light perception |

(Continued)
### Table 4. (Continued)

| References       | Filler Used | Ocular Adverse Event                                                                 | Management                                                                                       | Outcome                                                                                     |
|------------------|-------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Chen et al.⁵²    | HA          | Visual acuity impairment and ischemic oculomotor nerve palsy after injection of HA into the nasal dorsum | Cefuroxime and dexamethasone are given immediately without benefit; topical timolol maleate, tobramycin-dexamethasone ophthalmic eye drops, ocular massage. Additional treatments included intravenous injection of prostaglandin, periorcular injection of anisodamine to dilate arteries, iv injection of dextran 40, iv injection of ozagrel, and oxygen inhalation. Intramuscular injection of methyl cobalamin was given, systemic steroid dexamethasone is given for 3 d, and a topical antibacterial agent was applied to the affected skin for 10 d | Visual acuity, extraocular movement, and visual field defects improved within 14 d            |
| Hu et al.⁵³      | HA          | Sudden visual loss of the right eye                                                  | Hyaluronidase was injected into the forehead, glabella, nose, and retrobulbar region; 2 h of daily hyperbaric oxygen therapy, oral aspirin, oral acetazolamide, and iv dexamethasone | At 2 wk follow-up, patient showed improved visual acuity of the right eye to hand movements |
| Cohen et al.³⁴   | Calcium hydroxylapatite | Right eye periocular pain and blurred vision                                      | Immediate management: injected material tried to be withdrawn by aspiration, hot water compress, topical massage. Treatment: Enoxaparin, acetylsalicylic acid, amoxicillin/clavulanate, prednisone, topical antibiotics-ofloxacin, and mupirocin ointment | At two-mo follow-up, best corrected visual acuity was 20/32 in the right eye and 20/20 in the left eye. At 18-mo follow up; visual acuity declined to 20/60, visual field showed severe progressive deterioration with a central and superonasal field remnant and the optic disc became pale. |
| Goodman and Clague⁵⁵ | HA          | Immediate and partial loss of vision                                                 | Hyaluronidase, 375 IU/mL Approximately, 0.8 mL of hyaluronidase twice in short succession into the area of the supratrochlear and supraorbital notches | Second injection resulted in instant relief of visual symptoms and return of eyesight         |
| Dagi et al.³⁶    | Calcium hydroxylapatite | Horizontal diplopia and right upper eyelid ptosis                                   | A short course of oral steroids                                                                   | Moderate clinical improvement with interval resolution of the inflammation and enhancement of the right temporals, lacrimal gland, and lateral rectus muscle was noted on computerised tomography (CT) |
| Lee et al.³⁷     | HA          | Severe pain, blepharoptosis, and decreased visual acuity immediately after injection | Hyaluronidase injection, systemic steroid injections for 2 wk, broad spectrum antibiotics for 1 wk | 1 wk later recovered from blepharoptosis and limited extraocular movement had improved. By 6 mo, persistent diplopia progressively resolved In the 2 y follow-up, visual acuity remained stable, no visual deficits in the visual field and Optical coherence tomography (OCT) have shown no further decrease in ganglion cell activity (GCC). |
| Szantyr et al.³⁸ | Autologous fat | Ocular pain, complete visual loss, with no light perception in the right eye         | Prolonged circular digital and contact lens-induced ocular massage, ocular drops (timolol, brimonidine, and dorzolamide), IV dexamethasone, mannitol, glycerol; acetazolamide per os | (Continued)                                                                                 |
Table 4. (Continued)

| References          | Filler Used | Ocular Adverse Event                                                                 | Management                                                                 | Outcome |
|---------------------|-------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------|
| Myung et al.        | HA          | Blindness without ptosis. Ophthalmoplegia (n = 2); blindness and ptosis without ophthalmoplegia (n = 2); blindness and ophthalmoplegia without ptosis (n = 2); blindness with ptosis and ophthalmoplegia (n = 3) | NR                                                                 |         |
| Zhu et al.          | HA          | Immediate vision loss (n = 3), vision loss after 1 h (n = 1) 3 patients presented with retinal artery occlusion with retinal opacity and edema; 1 patient presented with no light perception in her left eye | Hyaluronidase (n = 4) and corticosteroids (n = 5)                          |         |
| Marumo et al.       | Calcium hydroxylapatite | Diplopia, visual loss in the left eye, and impaired consciousness | Subconjunctival injection and systemic administration corticosteroids | At 2 mo, diplopia and visual loss issues were mostly resolved          |
| Sharudin et al.     | HA          | Sudden onset of right monocular visual impairment associated with diplopia             | Subcutaneous hyaluronidase injection                                     | Complete visual recovery within 2 wk                                  |
| Thnasarnaksorn et al. | HA          | Vision loss secondary to HA embolization in retinal or ophthalmic arteries; with complications including periorbital pain, ptosis, impairment of extraocular muscle functionality | Patient 1: Hyaluronidase, hyperbaric oxygen therapy, and low-level laser therapy, anterior chamber paracentesis, methylprednisolone and antiplatelet drugs given along with oral antibiotics. Patient 2: Carbogen, right ocular massage, hyaluronidase injection, hyperbaric oxygen, oral eptazolamide, eye drop consisting of dorzolamide combined with timolol, and oral aspirin. Patient 3: Hyaluronidase injection, nitroglycerin transsoft tissue pad on the chest, ocular massage, breathed into a plastic bag. Patient 4: Hydrobaric oxygen, hyaluronidase injection, retrobulbar hyaluronidase injection. Patient 5: Intraseational hyaluronidase injection and retrobulbar hyaluronidase injection, nitroglycerin transsoft tissue pad, ocular massage and rebreathing in plastic bag. Patient 6: Hyaluronidase injection, ocular massage, hyperbaric oxygen | Patient 1: Received artificial eye, 6 mo later; Patient 2: After 21 d, ptosis completely resolved until full recovery 30 d after the incident; Patient 3: After 5 d, normal extraocular muscle function, visual field test normal; Patient 4: Extraocular muscles (EOM) function and ptosis continued to improve until full recovery 6 d later gradually; Patient 5: Ptosis and EOM function partially improved 20 d after initial injury, ophthalmoplegia almost fully recovered at 30 d; however, visual acuity of the left eye was still limited to light perception; Patient 6: Full recovery of vision |
| Liu et al.          | Autologous fat | Visual changes in the ipsilateral eye that progressed toward full visual loss Ophthalmic artery occlusion and/or hemiplegia | Injection discontinued, hyaluronidase, and aspirin | Full recovery of vision                                               |
|                    |             |                                                                                       |                                                                            | Unilateral permanent blindness                                         |
reaction over and above the mechanical blockage accentuating the obstruction and consequently cause ischemia and blindness. In fact, it has been shown that HA may have heparin-like activity as opposed to collagens clot promoting action.\(^5\)

**Can Blindness due to HA Injection Be Prevented or Treated?**

It has been seen that hyaluronidase, an enzyme that degrades HA, may improve outcomes following an accidental intravascular HA filler injection. A review conducted by Carruthers et al\(^5\) showed that when hyaluronidase was injected next to a blood vessel clogged with HA, it catabolized the HA without needing to canalize the affected artery. It is also suggested that in the case of retinal artery embolization with the HA product, retrobulbar injection of a large volume of hyaluronidase might well be the single most effective option to dissolve the intraorbital intravascular hyaluronic in a time-sensitive manner.\(^5\)

In 2018, a case reported by Sharudin et al\(^4\) showed a complete visual recovery of posterior ischemic optic neuropathy with ophthalmoplegia caused by HA filler injection. It has been suggested that in the case of embolism caused by HA, hyaluronidase given within the window period of 60–90 min has a strong chance of dissolving HA embolism.\(^6\) Another series of 6 cases of vision loss caused by HA filler injection showed improved visual acuity or complete reversal in 4 of the cases. The authors suggested that early supratrochlear/supraorbital hyaluronidase injection, ocular massage, and rebreathing into a plastic bag can be safe, uncomplicated and effective methods to enable restoration of the retinal circulation, and reverse vision loss.\(^7\) Chesnut\(^8\) also reported a case of recovery of HA filler visual loss after using retrobulbar hyaluronidase injection, although Zhu et al\(^9\) reported no recovery of vision loss in all 4 reported cases despite the use of retrobulbar hyaluronidase; albeit, these cases were all injected after 4 hours of occlusion and did not fall in the window of 60–90 min of perceived best opportunity for visual slavage.

Although consensus recommendations for the avoidance and management of complications from HA fillers including blindness are available,\(^10\) there is no evidence that following the currently available guidelines would reverse the vision loss necessitating a need for a specific protocol that can be followed to universally reverse all cases of blindness secondary to HA fillers. However, it is worthy to note that this possibility of reversal of iatrogenic blindness is likely to be possible with HA fillers and not others like autologous fat, collagen, or calcium hydroxyapatite.

Inconsistencies in recommendations for safer injection technique and lack of evidence to correlate the impact of injection technique on the occurrence of blindness necessitate the need for exploratory research. Better reporting of cases of blindness through a registry with details of the injection technique provided, including type of filler, use of needle or cannula (with size), use of local anesthesia, etc., can help to better understand the mechanism for the causation of blindness retrospectively so that preventive measures can be put in place. Additionally, the effect of different fillers (including the various brands of HA fillers available worldwide) on the vessel wall can be studied in vitro to establish the safety profile of the differently available fillers.

**LIMITATIONS**

This systematic review has many limitations. First, there was no uniformity in presenting the cases, and many important parameters or variables were not reported. Second, as with any case reports, the information regarding the rate, ratios, incidences, or prevalence cannot be generated because they are not representative of the population. Last, as with descriptive studies, one cannot deduce the cause–effect relationship; hence, the findings cannot be generalized.

**CONCLUSIONS**

Even though rare, vision loss due to HA injection is a disastrous event. When vision loss occurs, with limited time for restoration, early recognition and prompt treatment are crucial. There is no gold standard for the treatment of vision loss, and even though there have been consensus recommendations, no specific guidelines are available which have been universally successful in reversing this complication.

HA-based fillers appear to be relatively safer soft-tissue fillers, although it will be prudent to say that profound medical, anatomical, and product knowledge are required to minimize the occurrence of grave adverse reactions such as blindness associated with their use.

---

**REFERENCES**

1. Patzer GL. Improving self-esteem by improving physical attractiveness. *J Esthet Dent*. 1997;9:44–46.
2. Belezmay K, Carruthers JD, Humphrey S, et al. Avoiding and treating blindness from fillers: a review of the world literature. *Dermatol Surg*. 2015;41:1097–1117.
3. Haneke E. Managing complications of fillers: rare and not-so-rare. *J Cutan Aesthet Surg*. 2015;8:198–210.
4. Ferneini EM, Ferneini AM. An overview of vascular adverse events associated with facial soft tissue fillers: recognition, prevention, and treatment. *J Oral Maxillofac Surg*. 2016;74:1630–1636.
5. Humzah MD, Ataullah S, Chiang C, et al. The treatment of hyaluronic acid aesthetic interventional induced visual loss (AIVL): a consensus on practical guidance. *J Cosmet Dermatol*. 2019;18:71–76.
6. Kumar N, Rahman E. Effectiveness of teaching facial anatomy through cadaver dissection on aesthetic physicians’ knowledge. *Adv Med Educ Pract*. 2017;8:475–480.
7. Kumar N, Swift A, Rahman E. Development of “core syllabus” for facial anatomy teaching to aesthetic physicians: a Delphi consensus. *Plast Reconstr Surg Glob Open*. 2018;6:e1687.
8. Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151:264–269, W64.
9. Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60–63.

10. Danesh-Meyyer JH, Savino PJ, Sergott RC. Ocular and cerebral ischemia following facial injection of autologous fat. JAMA Ophthalmol. 2001;119:777–778.

11. Silva MT, Curi AL. Blindness and total ophthalmoplegia after aesthetic polyethylene glycol injection: case report. Arq Neuropsiquiatr. 2004;62:873–874.

12. Mori K, Ohta K, Nagano S, et al. A case of ophthalmic artery obstruction following autologous fat injection in the glabellar area. Nippon Ganka Gakkai Zasshi. 2007;111:22–25.

13. Park SH, Sun HJ, Choi KS. Sudden unilateral visual loss after autologous fat injection into the nasolabial fold. Clin Ophthalmol. 2008;2:679–683.

14. Sung MS, Kim HG, Woo KI, et al. Blindness ischemia and ischemic ocular motor nerve palsy after vascular embolization of injectable calcium hydroxyapatite filler. Ophthal Clin Ophthalmol. 2010;26:289–291.

15. Lee YJ, Kim HJ, Choi KD, et al. MRI restricted diffusion in optic nerve infarction after autologous fat transplantation. J Neuroophthalmol. 2010;30:216–218.

16. Park Y-H, Kim KS. Blindness after fat injections. N Engl J Med. 2011;365:2220–2223.

17. Lee CM, Hong IH, Park SP. Ophthalmic artery obstruction and cerebral infarction following periocular injection of autologous fat. Korean J Ophthalmol. 2011;25:358–361.

18. Lazzieri D, Agostini T, Figus M, et al. Blindness following cosmetic injections of the face. Plast Reconstr Surg. 2012;129:995–1012.

19. Park SW, Woo SJ, Park KH, et al. Iatrogenic retinal artery occlusion caused by systemic facial filler injections. Am J Ophthalmol. 2012;154:653–662.e1.

20. Oztrak CN, Li Y, Tung R, et al. Complications following injection of soft-tissue fillers. Aesthet Surg J. 2013;33:862–877.

21. Kim SN, Byun DS, Park JH, et al. Panophthalamplegia and vision loss after cosmetic nasal dorsum injection. J Clin Neurosci. 2014;21:678–680.

22. Chen Y, Wang W, Li J, et al. Fundus artery occlusion caused by cosmetic facial injections. Clin Med (Engl). 2014;127:1434–1437.

23. Carle MV, Roe R, Novack R, et al. Cosmetic facial fillers and severe vision loss. JAMA Ophthalmol. 2014;132:637–639.

24. Park KH, Kim YK, Woo SJ, et al.; Korean Retina Society. Iatrogenic occlusion of the ophthalmic artery after cosmetic facial filler injections: a national survey by the Korean Retina Society. JAMA Ophthalmol. 2014;132:714–723.

25. Hong DK, Seo YJ, Lee JH, et al. Sudden visual loss and multiple cerebral infarction after autologous fat injection into the glabella. Dermatol Surg. 2014;40:485–487.

26. Chang TY, Pan SC, Huang YH, et al. Blindness after calcium hydroxyapatite injection at nose. J Plast Reconstr Aesthet Surg. 2014;67:1755–1757.

27. Lee WS, Yoon WT, Choi YJ, et al. Multiple cerebral infarctions with neurological symptoms and ophthalmic artery occlusion after filler injection. J Korean Ophthalmol Soc. 2015;56:285–290.

28. Kim DY, Eom JS, Kim YJ. Temporary blindness after an anterior chamber cosmetic filler injection. Aesthetic Plast Surg. 2015;39:428–430.

29. Hsieh VH, Lin CW, Huang JS, et al. Severe ocular complications following facial calcium hydroxyapatite injections: Two case reports. Taiwan J Ophthalmol. 2015;5:96–99.

30. Chou CC, Chen HH, Tsai YY, et al. Choroidal vascular occlusion and ischemic optic neuropathy after facial calcium hydroxyapatite injection—a case report. BMC Surg. 2015;15:21.

31. Qi X, Zhou J, Ma L, et al. Analysis of artery occlusion caused by facial autologous fat injections. Dig Med. 2015;1:39–42.

32. Chen W, Wu L, Jian XL, et al. Retinal branch artery embolization following hyaluronic acid injection: a case report. Aesthet Surg J. 2016;36:219F–219G.

33. Hu XZ, Hu JY, Wu PS, et al. Posterior ciliary artery occlusion caused by hyaluronic acid injections into the forehead: a case report. Medicine (Baltimore). 2016;95:e3124.

34. Cohen E, Yatzis V, Leibovitch I, et al. A case report of ophthalmic artery emboli secondary to calcium hydroxyapatite filler injection for nose augmentation- long-term outcome. BMC Ophthalmol. 2016;16:98.

35. Goodman GJ, Cagle MD. A rethink on hyalurondiase injection, intraarterial injection, and blindness: is there another option for treatment of retinal artery emboli caused by intraarterial injection of hyaluronic acid? Dermatol Surg. 2016;22:547–549.

36. Dagi Glass LR, Choi C, Lee NG. Orbital complication following calcium hydroxyapatite filler injection. Ophthal Plast Reconstr Surg. 2017;33:S16–S17.

37. Lee JI, Kang SJ, Sun H. Skin necrosis with oculumotor nerve palsy due to a hyaluronic acid filler injection. Arch Plast Surg. 2017;44:340–343.

38. Szantyr A, Orsöi M, Marchewka I, et al. Ocular complications following autologous fat injections into facial area: case report of a recovery from visual loss after ophthalmic artery occlusion and a review of the literature. Aesthetic Plast Surg. 2017;41:580–584.

39. Myung Y, Yim S, Jeong JH, et al. The classification and prognosis of periocular complications related to blindness following cosmetic filler injection. Plast Reconstr Surg. 2017;140:61–64.

40. Zhu GZ, Sun ZS, Liao WX, et al. Efficacy of retrobulbar hyalurondiase injection for vision loss resulting from hyaluronic acid filler embolization. Aesthet Surg J. 2017:38:12–22.

41. Marumo Y, Hiraoka M, Hashimoto M, et al. Visual impairment by multiple vascular embolization with hydroxyapatite particles. Orbit. 2018;37:165–170.

42. Sharudin SN, Ismail MF, Mohamad NF, et al. Complete recovery of filler-induced visual loss following subcutaneous hyalurondiase injection. JAMA Ophthalmol. 2018;10:1080/01658107.2018.1482558.

43. Thanasarnakorn W, Cotofana S, Rudolph C, et al. Severe vision loss caused by cosmetic filler augmentation: case series with review of cause and therapy. J Cosmet Dermatol. 2018;17:712–718.

44. Chesnut C. Restoration of visual loss with retrobulbar hyalurondiase injection after hyaluronic acid filler embolization. Dermatol Surg. 2018;44:435–437.

45. Liu H, Chen D, Zhang J. Ophthalmic artery occlusion after forehead autologous fat injection. Retin Cases Brief Rep. 2018;doi:10.1097/ICB.0000000000000694.

46. Jang JG, Hong KS, Choi YE. A case of nonthrombotic pulmonary embolism after facial injection of hyaluronic Acid in an illegal cosmetic procedure. Tuberc Respir Dis (Seoul). 2014;77:90–93.

47. Fermeini EM, Hapelas S, Watras J, et al. Surgeon’s guide to facial soft tissue filler injections: relevant anatomy and safety considerations. J Oral Maxillofac Surg. 75: e1–e5.

48. Povolotskiy R, Olek NC, Hatzis CM, et al. Adverse events associated with aesthetic dermal fillers: 10-year retrospective study of FDA data. Ann J Cosmet Surg. 2018;35:143–51.

49. Zheng H, Qiu L, Liu Z, et al. Exploring the possibility of a retrograde embolism pathway from the facial artery to the ophthalmic artery system in vivo. Aesthetic Plast Surg. 2017;41:1222–1227.

50. Prado G, Rodríguez-Feliz J. Ocular pain and impending blindness during facial cosmetic injections. J Cosmet Dermatol. 2018;17:712–718.

51. Li B, Allen LH, Sheidow TG. Vision loss and vascular compromise with facial and periorbicular injections. Can J Ophthalmol. 2015;50:e57–e60.
52. Rzany B, DeLorenzi C. Understanding, Avoiding, and managing severe filler complications. *Plast Reconstr Surg*. 2015;136(5 Suppl):1968–2038.

53. Kim YK, Jung C, Woo SJ, et al. Cerebral angiographic findings of cosmetic facial filler-related ophthalmic and retinal artery occlusion. *J Korean Med Sci*. 2015;30:1847–1855.

54. Cho KH, Pozza ED, Toth G, et al. Pathophysiologic study of filler-induced blindness. *Aesthet Surg J*. 2019;39:96–106.

55. Sufan W, Lei P, Hua W, et al. Anatomic study of ophthalmic artery embolism following cosmetic injection. *J Craniofac Surg*. 2017;28:1578–1581.

56. Kim A, Kim SH, Kim HJ, et al. Ophthalmoplegia as a complication of cosmetic facial filler injection. *Acta Ophthalmol*. 2016;94:e377–e379.

57. Pierre S, Liew S, Bernardin A. Basics of dermal filler rheology. *Dermatol Surg*. 2015;41(Suppl 1):S120–S126.

58. Sorensen EP, Urman C. Cosmetic complications: rare and serious events following botulinum toxin and soft tissue filler administration. *J Drugs Dermatol*. 2015;14:486–491.

59. Carruthers JD, Fagien S, Rohrich RJ, et al. Blindness caused by cosmetic filler injection: a review of cause and therapy. *Plast Reconstr Surg*. 2014;134:1197–1201.

60. Signorini M, Liew S, Sundaram H, et al.; Global Aesthetics Consensus Group. Global aesthetics consensus: avoidance and management of complications from hyaluronic acid fillers—evidence- and opinion-based review and consensus recommendations. *Plast Reconstr Surg*. 2016;137:961e–971e.